YahooFinance

Kite Pharma, Inc. KITE announced that it has finished the filing of a rolling conformity of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.

We note that axicabtagene ciloleucel is Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Continue reading →